Potential application of lithium in Parkinson's and other neurodegenerative diseases

Frontiers in Neuroscience

Volumn 9, Issue OCT, 2015, Pages

  Lazzara, Carol A ^a   Kim, Yong Hwan ^a  

^a DELAWARE STATE UNIVERSITY   (United States)

Author keywords

And autophagy; Bcl 2; Calpain; GSK 3 ; Neuroprotection

Indexed keywords

ALPHA SYNUCLEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CALPAIN; CARBIDOPA PLUS LEVODOPA; CYCLIN DEPENDENT KINASE 5; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; AUTOPHAGY; DEGENERATIVE DISEASE; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; EXCITOTOXICITY; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

EID: 84946562056     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2015.00403     Document Type: Review

References (127)

1. Abou-Saleh, M. T., and Coppen, A. (1989). The efficacy of low-dose lithium: clinical, psychological and biological correlates. J. Psychiatr. Res. 23, 157-162. doi: 10.1016/0022-3956(89)90006-X
2. Aggarwal, S. P., Zinman, L., Simpson, E., McKinley, J., Jackson, K. E., Pinto, H., et al. (2010). Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9, 481-488. doi: 10.1016/S1474-4422(10)70068-5
3. Alural, B., Ozerdem, A., Allmer, J., Genc, K., and Genc, S. (2015). Lithium protects against paraquat neurotoxicity by NRF2 activation and miR-34a inhibition in SH-SY5Y cells. Front. Cell. Neurosci. 9:209. doi: 10.3389/fncel.2015.00209
4. Alvarez, G., Muñoz-Montaño, J. R., Satrustegui, J., Avila, J., Bogonez, E., and Diaz-Nido, J. (1999). Lithium protects cultured neurons against L-amyloid-induced neurodegeneration. FEBS Lett. 453, 260-264.
5. Aminoff, M. J., and Marshall, J. (1974). Treatment of Huntington's chorea with lithium carbonate: a double-blind trial. Lancet 7848, 107-109. doi: 10.1016/S0140-6736(74)92339-3
6. Avila, J., and Hernández, F. (2007). GSK-3 inhibitors for Alzheimer's disease. Expert Rev. Neurother. 7, 1527-1533. doi: 10.1586/14737175.7.11.1527
7. Avila, J., León-Espinosa, G., García, E., García-Escudero, V., Hernández, F., and DeFelipe, J. (2012). Tau phosphorylation by GSK3 in different conditions. Int. J. Alzheimers Dis. 2012:578373. doi: 10.1155/2012/578373
8. Bhat, R. V., Haeberlein, S. L. B., and Avila, J. (2004). Glycogen synthase kinase 3: a drug target for CNS therapies. J. Neurochem. 89, 1313-1317. doi: 10.1111/j.1471-4159.2004.02422.x
9. Baldessarini, R. J., Tondo, L., Davis, P., Pompili, M., Goodwin, F. K., and Hennen, J. (2006). Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord. 8, 625-639. doi: 10.1111/j.1399-5618.2006.00344.x
10. Basselin, M., Chang, L., Bell, J. M., and Rapoport, S. I. (2006). Chronic lithium chloride administration attenuates brain NMDA receptor-initiated signaling via arachidonic acid in unanesthetized rats. Neuropsychopharmacology 31, 1659-1674. doi: 10.1038/sj.npp.1300920
11. Basu, A., and Haldar, S. (1998). The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death. Mol. Hum. Reprod. 4, 1099-1109. doi: 10.1093/molehr/4.12.1099
12. Bauer, M., Alda, M., Priller, J., and Young, L. T. (2003). Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders. Pharmacopsychiatry 36, 250-254. doi: 10.1055/s-2003-45138
13. Beaulieu, J. M., Sotnikova, T. D., Yao, W. D., Kockeritz, L., Woodgett, J. R., Gainetdinov, R. R., et al. (2004). Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. U.S.A. 101, 5099-5104. doi: 10.1073/pnas.0307921101
14. Beaulieu, J. M., Gainetdinov, R. R., and Caron, M. G. (2007). The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends. Pharmacol. Sci. 28, 166-172. doi: 10.1016/j.tips.2007.02.006
15. Berger, Z., Ttofi, E. K., Michel, C. H., Pasco, M. Y., Tenant, S., Rubinsztein, D. C., et al. (2005). Lithium rescues toxicity of aggregate-prone proteins in Drosophila by perturbing Wnt pathway. Hum. Mol. Genet. 14, 3003-3011. doi: 10.1093/hmg/ddi331
16. Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., and Greenamyre, J. T. (2000). Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 1301-1306. doi: 10.1038/81834
17. Bosco, D. A., Fowler, D. M., Zhang, Q., Nieva, J., Powers, E. T., Wentworth, P., et al. (2006). Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate a-synuclein fibrilization. Nat. Chem. Biol. 2, 249-253. doi: 10.1038/nchembio782
18. Burstein, D. E., Seeley, P. J., and Greene, L. A. (1985). Lithium ion inhibits nerve growth factor-induced neurite outgrowth and phosphorylation of nerve growth factor-modulated microtubule-associated proteins. J. Cell Biol. 101, 862-870. doi: 10.1083/jcb.101.3.862
19. Carmichael, J., Sugars, K. L., Bao, Y. P., and Rubinsztein, D. C. (2002). Glycogen synthase kinase-3 inhibitors prevent cellular polyglutamine toxicity caused by the huntington's disease mutation. J. Biol. Chem. 277, 33791-33798. doi: 10.1074/jbc.M204861200
20. Chang, M. C., Grange, E., Rabin, O., Bell, J. M., Allen, D. D., and Rapoport, S. I. (1996). Lithium decreases turnover of arachidonate in several brain phospholipids. Neurosci. Lett. 220, 171-174. doi: 10.1016/S0304-3940(96)13264-X
21. Chang, M. C., and Jones, C. R. (1998). Chronic lithium treatment decreases brain phospholipase A2 activity. Neurochem. Res. 23, 887-892. doi: 10.1023/A:1022415113421
22. Chang, M. C., Contreras, M. A., Rosenberger, T. A., Rintala, J. J., Bell, J. M., and Rapoport, S. I. (2001). Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers. J. Neurochem. 77, 796-803. doi: 10.1046/j.1471-4159.2001.00311.x
23. Chen, C. L., Lin, C. F., Chiang, C. W., Jan, M. S., and Lin, Y. S. (2006). Lithium inhibits ceramide-and etoposide-induced protein phosphatase 2A methylation, Bcl-2 dephosphorylation, caspase-2 activation, and apoptosis. Mol. Pharmacol. 70, 510-517. doi: 10.1124/mol.106.024059
24. Chen, G., Bower, K. A., Ma, C., Fang, S., Thiele, C. J., and Luo, J. I. A. (2004). Glycogen synthase kinase 3ß (GSK3ß) mediates 6-hydroxydopamine-induced neuronal death. FASEB J. 18, 1162-1164. doi: 10.1096/fj.04-1551fje
25. Chen, G., Yuan, P. X., Jiang, Y. M., Huang, L. D., and Manji, H. K. (1998). Lithium increases tyrosine hydroxylase levels both in vivo and in vitro. J. Neurochem. 70, 1768-1771. doi: 10.1046/j.1471-4159.1998.70041768.x
26. Chen, G., Rajkowska, G., Du, F., Seraji-Bozorgzad, N., and Manji, H. K. (2000). Enhancement of hippocampal neurogenesis by lithium. J. Neurochem. 75, 1729-1734. doi: 10.1046/j.1471-4159.2000.0751729.x
27. Chen, R. W., and Chuang, D. M. (1999). Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression A prominent role in neuroprotection against excitotoxicity. J. Biol. Chem. 274, 6039-6042. doi: 10.1074/jbc.274.10.6039
28. Chen, R. W., Qin, Z. H., Ren, M., Kanai, H., Chalecka-Franaszek, E., Leeds, P., et al. (2003). Regulation of c-Jun N-terminal kinase, p38 kinase and AP-1 DNA binding in cultured brain neurons: roles in glutamate excitotoxicity and lithium neuroprotection. J. Neurochem. 84, 566-575. doi: 10.1046/j.1471-4159.2003.01548.x
29. Chi-Tso, C. T., and Chuang, D. M. (2011). Neuroprotective action of lithium in disorders of the central nervous system. J. Cent. South Univ. 36, 461-467. doi: 10.3969/j.issn.1672-7347.2011.06.001
30. Chiò, A., Borghero, G., Calvo, A., Capasso, M., Caponnetto, C., Corbo, M., et al. (2010). Lithium carbonate in amyotrophic lateral sclerosis lack of efficacy in a dose-finding trial. Neurology 75, 619-625. doi: 10.1212/WNL.0b013e3181ed9e7c
31. Chiu, C., Liu, G., Leeds, P., and Chuang, D. m. (2011). Combined Treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of huntington's disease. Neuropsychopharmacology 36, 2406-2421. doi: 10.1038/npp.2011.128
32. Cipriani, A., Pretty, H., Hawton, K., and Geddes, J. R. (2005). Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am. J. Psychiatry 162, 1805-1819. doi: 10.1176/appi.ajp.162.10.1805
33. Crespo-Biel, N., Camins, A., Pallàs, M., and Canudas, A. M. (2009). Evidence of calpain/cdk5 pathway inhibition by lithium in 3-nitropropionic acid toxicity in vivo and in vitro. Neuropharmacology 56, 422-428. doi: 10.1016/j.neuropharm.2008.09.012
34. Cruz, J. C., and Tsai, L. H. (2004). Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol. Med. 10, 452-458. doi: 10.1016/j.molmed.2004.07.001
35. Cui, J., Shao, L., Young, L. T., and Wang, J. F. (2007). Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 144, 1447-1453. doi: 10.1016/j.neuroscience.2006.11.010
36. Danivas, V., Moily, N. S., Thimmaiah, R., Muralidharan, K., Purushotham, M., Muthane, U., et al. (2013). Off label use of lithium in the treatment of Huntington's disease: a case series. Indian J. Psychiatry 55, 81. doi: 10.4103/0019-5545.105522
37. de Vasconcellos, A. P. S., Nieto, F. B., Crema, L. M., Diehl, L. A., de Almeida, L. M., Prediger, M. E., et al. (2006). Chronic lithium treatment has antioxidant properties but does not prevent oxidative damage induced by chronic variate stress. Neurochem. Res. 31, 1141-1151. doi: 10.1007/s11064-006-9139-2
38. Donaldson, I. M., and Cuningham, J. (1983). Persisting neurologic sequelae of lithium carbonate therapy. Arch. Neurol. 40, 747-751. doi: 10.1001/archneur.1983.04050110065011
39. Duka, T., Duka, V., Joyce, J. N., and Sidhu, A. (2009). a-Synuclein contributes to GSK-3ß-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J. 23, 2820-2830. doi: 10.1096/fj.08-120410
40. Dunn, N., Holmes, C., and Mullee, M. (2005). Does lithium therapy protect against the onset of dementia? Alzheimer Dis. Assoc. Disord. 19, 20-22. doi: 10.1097/01.wad.0000155068.23937.9b
41. Einat, H., Yuan, P., Gould, T. D., Li, J., Du, J., Zhang, L., et al. (2003). The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J. Neurosci. 23, 7311-7316.
42. Feng, H., Leng, Y., Ma, C., Zhang, J., Ren, M., and Chuang, D. (2008). Combined lithium and valproate treatment delatys disease onset, reduces neurological deficits and prolongs survival in an ALS mouse model. Neuroscience 155, 567-572 doi: 10.1016/j.neuroscience.2008.06.040
43. Finelli, P. F. (1992). Drug-induced Creutzfeldt-Jakob like syndrome. J. Psychiatry Neurosci. 17, 103-105.
44. Fiorentini, A., Rosi, M. C., Grossi, C., Luccarini, I., and Casamenti, F. (2010). Lithium improves hippocampal neurogenesis, neuropathology and cognitive functions in APP mutant mice. PLoS ONE 5:e14382. doi: 10.1371/journal.pone.0014382
45. Forlenza, O. V., Diniz, B. S., Radanovic, M., Santos, F. S., Talib, L. L., and Gattaz, W. F. (2011). Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br. J. Psychiatry 198, 351-356. doi: 10.1192/bjp.bp.110.080044
46. Fornai, F., Longone, P., Cafaro, L., Kastsiuchenka, O., Ferrucci, M., Manca, et al. (2008b). Lithium delays progression of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U.S.A. 105, 2052-2057. doi: 10.1073/pnas.0708022105
47. Fornai, F., Longone, P., Ferrucci, M., Lenzi, P., Isidoro, C., and Ruggieri, S. (2008a). Autophagy and amyotrophic lateral sclerosis. Autophagy 4, 527-530. doi: 10.4161/auto.5923
48. Frey, B. N., Andreazza, A. C., Kunz, M., Gomes, F. A., Quevedo, J., Salvador, M., et al. (2007). Increased oxidative stress and DNA damage in bipolar disorder: a twin-case report. Prog. Neuropsychopharmacol. Biol Psychiatry 31, 283-285. doi: 10.1016/j.pnpbp.2006.06.011
49. Friedlander, R. M. (2003). Apoptosis and caspases in neurodegenerative diseases. N. Engl. J. Med. 348, 1365-1375. doi: 10.1056/NEJMra022366
50. Fukumoto, T., Morinobu, S., Okamoto, Y., Kagaya, A., and Yamawaki, S. (2001). Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology 158, 100-106. doi: 10.1007/s002130100871
51. Fukushima, T., Tan, X., Luo, Y., Wang, P., Song, J., Kanda, H., et al. (2013). Heavy metals in blood and urine and its relation to depressive symptoms in Parkinson's disease patients. Fukushima J. Med. Sci. 59, 76-80. doi: 10.5387/fms.59.76
52. Ghadirian, A. M., and Lehmann, H. E. (1980). Neurological side effects of lithium: organic brain syndrome, seizures, extrapyramidal side effects, and EEG changes. Compr. Psychiatry 21, 327-335. doi: 10.1016/0010-440X(80)90013-9
53. Gould, T. D., Chen, G., and Manji, H. K. (2002). Mood stabilizer psychopharmacology. Clin. Neurosci. Res. 2, 193-212. doi: 10.1016/S1566-2772(02)00044-0
54. Gould, T. D., Chen, G., and Manji, H. K. (2004). In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 29, 32-38. doi: 10.1038/sj.npp.1300283
55. Gould, T. D., and Manji, H. K. (2005). Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30, 1223-1237. doi: 10.1038/sj.npp.1300731
56. Gsell, W., Conrad, R., Hickethier, M., Sofic, E., Frölich, L., Wichart, I., et al. (1995). Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J. Neurochem. 64, 1216-1223. doi: 10.1046/j.1471-4159.1995.64031216.x
57. Hampel, H., Ewers, M., Bürger, K., Annas, P., Mörtberg, A., Bogstedt, A., et al. (2009). Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J. Clin. Psychiatry 70, 1-10. doi: 10.4088/JCP.08m04606
58. Hanger, D. P., and Noble, W. (2011). Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation. Int. J. Alzheimers Dis. 2011:352805. doi: 10.4061/2011/352805
59. Hashimoto, R., Takei, N., Shimazu, K., Christ, L., Lu, B., and Chuang, D. M. (2002). Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 43, 1173-1179. doi: 10.1016/S0028-3908(02)00217-4
60. Hashimoto, R., Senatorov, V., Kanai, H., Leeds, P., and Chuang, D. M. (2003). Lithium stimulates progenitor proliferation in cultured brain neurons. Neuroscience 117, 55-61. doi: 10.1016/S0306-4522(02)00577-8
61. Helton, T. D., Otsuka, T., Lee, M.-C., Mu, Y., and Ehlers, M. D. (2008). Pruning and loss of excitatory synapses by the parkin ubiquitin ligase. Proc. Natl. Acad. Sci. U.S.A. 105, 19492-19497. doi: 10.1073/pnas.0802280105
62. Hong, M., Chen, D. C., Klein, P. S., and Lee, V. M. Y. (1997). Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J. Biol. Chem. 272, 25326-25332. doi: 10.1074/jbc.272.40.25326
63. Huang, X., Wu, D. Y., Chen, G., Manji, H., and Chen, D. F. (2003). Support of retinal ganglion cell survival and axon regeneration by lithium through a Bcl-2-dependent mechanism. Ophthalmol. Vis. Sci. 44, 347-354. doi: 10.1167/iovs.02-0198
64. Johnels, B., Wallin, L., and Wålinder, J. (1976). Extrapyramidal side effects of lithium treatment. Br. Med. J. 2, 642. doi: 10.1136/bmj.2.6036.642-a
65. Jope, R. S. (1999). A bimodal model of the mechanism of action of lithium. Mol. Psychiatry 4, 21-25. doi: 10.1038/sj.mp.4000444
66. Jordà, E. G., Verdaguer, E., Canudas, A. M., Jiménez, A., Garcia de Arriba, S., Allgaier, C., et al. (2005). Implication of cyclin-dependent kinase 5 in the neuroprotective properties of lithium. Neuroscience 134, 1001-1011. doi: 10.1016/j.neuroscience.2005.04.061
67. Kane, J., Rifkin, A., Quitkin, F., and Klein, D. F. (1978). Extrapyramidal side effects with lithium treatment. Am. J. Psychiatry 135, 851-853. doi: 10.1176/ajp.135.7.851
68. Kim, A. J., Shi, Y., Austin, R. C., and Werstuck, G. H. (2005). Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. J. Cell Sci. 118, 89-99. doi: 10.1242/jcs.01562
69. Kim, Y. H., Rane, A., Lussier, S., and Andersen, J. K. (2011). Lithium protects against oxidative stress-mediated cell death in a-synuclein-overexpressing in vitro and in vivo models of Parkinson's disease. Neurosci. Res. 89, 1666-1675. doi: 10.1002/jnr.22700
70. King, T. D., Bijur, G. N., and Jope, R. S. (2001). Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3ß and attenuated by lithium. Brain Res. 919, 106-114. doi: 10.1016/S0006-8993(01)03005-0
71. Klionsky, D. J., Abdalla, F. C., Abeliovich, H., Abraham, R. T., Acevedo-Arozena, A., Adeli, K., et al. (2012). Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8, 445-544. doi: 10.4161/auto.19496
72. Lau, A., and Tymianski, M. (2010). Glutamate receptors, neurotoxicity and neurodegeneration. Pflug. Arch. Eur. J. Phys. 460, 525-542. doi: 10.1007/s00424-010-0809-1
73. Lazzara, C. A., Riley, R. R., Rane, A., Andersen, J. K., and Kim, Y. H. (2015). The combination of lithium and L-Dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: relevance for Parkinson's disease therapy. Brain Res. 1622, 127-136. doi: 10.1016/j.brainres.2015.06.018
74. Leonard, D. P., Kidson, M. A., Brown, J. G., Shannon, P. J., and Taryan, S. (1975). A double blind trial of lithium carbonate and haloperidol in Huntington's chorea. Aust. N.Z. J. Psychiatry 9, 115-118. doi: 10.3109/00048677509159834
75. Li, X. Z, Chen, X. P, Zhao, K., Bai, L. M., Zhang, H., and Zhou, X. P. (2013). Therapeutic effects of valproate combined with lithium carbonate on MPTP-induced parkinsonism in mice: possible mediation through enhanced autophagy. Int. J. Neurosci. 123, 73-79. doi: 10.3109/00207454.2012.729234
76. Liang, M. H., Wendland, J. R., and Chuang, D. M. (2008). Lithium inhibits Smad3/4 transactivation via increased CREB activity induced by enhanced PKA and AKT signaling. Mol. Cell Neurosci. 37, 440-453. doi: 10.1016/j.mcn.2007.10.017
77. Lieu, C. A., Dewey, C. M., Chinta, S. J., Rane, A., Rajagopalan, S., Batir, S., et al. (2014). Lithium prevents parkinsonian behavioral and striatal phenotypes in an aged parkin mutant transgenic mouse model. Brain Res. 1591, 111-117. doi: 10.1016/j.brainres.2014.10.032
78. Lindholm, D., Wootz, H., and Korhonen, L. (2006). ER stress and neurodegenerative diseases. Cell Death Differ. 13, 385-392. doi: 10.1038/sj.cdd.4401778
79. Lowthert, L., Leffert, J., Lin, A., Umlauf, S., Maloney, K., Muralidharan, A., et al. (2012). Increased ratio of anti-apoptotic to pro-apoptotic Bcl2 gene-family members in lithium-responders one month after treatment initiation. Biol. Mood Anxiety Disord. 2, 15-15. doi: 10.1186/2045-5380-2-15
80. Machado-Vieira, R., Andreazza, A. C., Viale, C. I., Zanatto, V., Cereser, V. Jr., da Silva Vargas, R., et al. (2007). Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci. Lett. 421, 33-36. doi: 10.1016/j.neulet.2007.05.016
81. Makoukji, J., Belle, M., Meffre, D., Stassart, R., Grenier, J., Shackleford, G., et al. (2012). Lithium enhances remyelination of peripheral nerves. Proc. Natl. Acad. Sci. U.S.A. 109, 3973-3978. doi: 10.1073/pnas.1121367109
82. McAllister, A. K., Katz, L. C., and Lo, D. C. (1999). Neurotrophins and synaptic plasticity. Annu. Rev. Neurosci. 22, 295-318. doi: 10.1146/annurev.neuro.22.1.295
83. Miller, R. G., Moore, D. H., Forshew, D. A., Katz, J. S., Barohn, R. J., Valan, M., et al. (2011). Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis Examining a more efficient trial design. Neurology 77, 973-979. doi: 10.1212/WNL.0b013e31822dc7a5
84. Mudò, G., Jiang, X. H., Timmusk, T., Bindoni, M., and Belluardo, N. (1996). Change in neurotrophins and their receptor mRNAs in the rat forebrain after status epilepticus induced by pilocarpine. Epilepsia 37, 198-207. doi: 10.1111/j.1528-1157.1996.tb00012.x
85. Muñoz-Montaño, J. R., Moreno, F. J., Avila, J., and Diaz-Nido, J. (1997). Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett. 411, 183-188.
86. Nakabeppu, Y., Tsuchimoto, D., Yamaguchi, H., and Sakumi, K. (2007). Oxidative damage in nucleic acids and Parkinson's disease. J. Neurosci. Res. 85, 919-934. doi: 10.1002/jnr.21191
87. Nciri, R., Desmoulin, F., Allagui, M. S., Murat, J. C., Feki, A. E., Vincent, C., et al. (2013). Neuroprotective effects of chronic exposure of SH-SY5Y to low lithium concentration involve glycolysis stimulation, extracellular pyruvate accumulation and resistance to oxidative stress. Int. J. Neuropsychopharmacol. 16, 365-376. doi: 10.1017/S1461145712000132
88. Nciri, R., Boujbiha, M. A., Jbahi, S., Allagui, M. S., Feki, A. E., Vincent, C., et al. (2015). Cytoskeleton involvement in lithium-induced SH-SY5Y neuritogenesis and the role of glycogen synthase kinase 3ß. Aging Clin. Exp. Res. 27, 255-263. doi: 10.1007/S40520-014-0390-3
89. Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., et al. (2005). Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. U.S.A. 102, 6990-6995. doi: 10.1073/pnas.0500466102
90. Nonaka, S., Hough, C. J., and Chuang, D. M. (1998). Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc. Natl. Acad. Sci. U.S.A. 95, 2642-2647. doi: 10.1073/pnas.95.5.2642
91. Nunes, P. V., Forlenza, O. V., and Gattaz, W. F. (2007). Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Brit. J. Psychiatry 190, 359-360. doi: 10.1192/bjp.bp.106.029868
92. Offen, D., Beart, P. M., Cheung, N. S., Pascoe, C. J., Hochman, A., Gorodin, S., et al. (1998). Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 95, 5789-5794. doi: 10.1073/pnas.95.10.5789
93. O'Leary, O. F., O'Connor, R. M., and Cryan, J. F. (2012). Lithium-induced effects on adult hippocampal neurogenesis are topographically segregated along the dorso-ventral axis of stressed mice. Neuropharmacology 62, 247-255. doi: 10.1016/j.neuropharm.2011.07.015
94. Oltval, Z. N., Milliman, C. L., and Korsmeyer, S. J. (1993). Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death. Cell 74, 609-619. doi: 10.1016/0092-8674(93)90509-O
95. Parkinson, J. (2002). An essay on the shaking palsy. J. Neuropsychiatry Clin. Neurosci. 14, 223-236. doi: 10.1176/jnp.14.2.223
96. Plattner, F., Angelo, M., and Giese, K. P. (2006). The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J. Biol. Chem. 281, 25457-25465. doi: 10.1074/jbc.M603469200
97. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., et al. (1997). Mutation in the a-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
98. Rapoport, S. I., and Bosetti, F. (2002). Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch. Gen. Psychiatry 59, 592-596. doi: 10.1001/archpsyc.59.7.592
99. Rintala, J., Seemann, R., Chandrasekaran, K., Rosenberger, T. A., Chang, L., Contreras, M. A., et al. (1999). 85 kDa cytosolic phospholipase A2 is a target for chronic lithium in rat brain. Neuroreport 10, 3887-3890. doi: 10.1097/00001756-199912160-00030
100. Rowe, M. K., and Chuang, D. M. (2004). Lithium neuroprotection: molecular mechanisms and clinical implications. Expert Rev. Mol. Med. 6, 1-18. doi: 10.1017/S1462399404008385
101. Rowe, M. K., Wiest, C., and Chuang, D. M. (2007). GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci. Biobehav. Rev. 31, 920-931. doi: 10.1016/j.neubiorev.2007.03.002
102. Ruvolo, P. P., Deng, X., and May, W. S. (2001). Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia 15, 515-522. doi: 10.1038/sj.leu.2402090
103. Sarkar, S., Floto, R. A., Berger, Z., Imarisio, S., Cordenier, A., Pasco, M., et al. (2005). Lithium induces autophagy by inhibiting inositol monophosphatase. J. Cell Biol. 170, 1101-1111. doi: 10.1083/jcb.200504035
104. Sarkar, S., and Rubinsztein, D. C. (2006). Addenda inositol and IP3 levels regulate autophagy. Autophagy 2, 132-134. doi: 10.4161/auto.2387
105. Sarkar, S., and Rubinsztein, D. C. (2008). Small molecule enhancers of autophagy for neurodegenerative diseases. Mol. Biosyst. 4, 895-901. doi: 10.1039/b804606a
106. Sarkar, S., Krishna, G., Imarisio, S., Saiki, S., O'Kane, C. J., and Rubinsztein, D. C. (2008). A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum. Mol. Genet. 17, 170-178. doi: 10.1093/hmg/ddm294
107. Sasaki, T., Han, F., Shioda, N., Moriguchi, S., Kasahara, J., Ishiguro, K., et al. (2006). Lithium-induced activation of Akt and CaM kinase II contributes to its neuroprotective action in a rat microsphere embolism model. Brain Res. 1108, 98-106. doi: 10.1016/j.brainres.2006.06.009
108. Senatorov, V. V., Ren, M., Kanai, H., Wei, H., and Chuang, D. (2004). Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease. Mol. Psychiatry 9, 371-385. doi: 10.1038/sj.mp.4001463
109. Shao, L., Young, L. T., and Wang, J. F. (2005). Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol. Psychiatry 58, 879-884. doi: 10.1016/j.biopsych.2005.04.052
110. Smith, S. J., and Kocen, R. S. (1988). A Creutzfeldt-Jakob like syndrome due to lithium toxicity. J. Neurol. Neurosurg. Psychiatry 51, 120-123. doi: 10.1136/jnnp.51.1.120
111. Smith, L. A., Cornelius, V., Warnock, A., Bell, A., and Young, A. H. (2007). Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord. 9, 394-412. doi: 10.1111/j.1399-5618.2007.00490.x
112. Smith, P. D., Mount, M. P., Shree, R., Callaghan, S., Slack, R. S., Anisman, H., et al. (2006). Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2. J. Neurosci. 26, 440-447. doi: 10.1523/JNEUROSCI.2875-05.2006
113. Stambolic, V., Ruel, R., and Woodgett, J. R. (1996). Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr. Biol. 6, 1664-1668. doi: 10.1016/S0960-9822(02)70790-2
114. Stelmashook, E. V., Isaev, N. K., Genrikhs, E. E., Amelkina, G. A., Khaspekov, L. G., Skrebitsky, V. G., et al. (2014). Role of zinc and copper ions in the pathogenetic mechanisms of Alzheimer's and Parkinson's diseases. Biochemistry (Mosc.). 79, 391-396. doi: 10.1134/S0006297914050022
115. Su, H., Chu, T. H., and Wu, W. (2007). Lithium enhances proliferation and neuronal adult rat spinal cord. Exp. Neurol. 206, 296-307. doi: 10.1016/j.expneurol.2007.05.018
116. Su, H., Zhang, W., Guo, J., Guo, A., Yuan, Q., and Wu, W. (2009). Lithium enhances the neuronal differentiation of neural progenitor cells in vitro and after transplantation into the avulsed ventral horn of adult rats through the secretion of brain-derived neurotrophic factor. J. Neurochem. 108, 1385-1398. doi: 10.1111/j.1471-4159.2009.05902.x
117. Sundaram, J. R., Poore, C. P., Sulaimee, N. H. B., Pareek, T., Asad, A. B. M. A., Rajkumar, R., et al. (2013). Specific inhibition of p25/Cdk5 activity by the Cdk5 inhibitory peptide reduces neurodegeneration in vivo. J. Neurosci. 33, 334-343. doi: 10.1523/JNEUROSCI.3593-12.2013
118. Vestergaard, P., Baastrup, P. C., and Petersson, H. (1977). Lithium treatment of Huntington's chorea: a placebo-controlled clinical trial. Acta Psychiatr. Scand. 56, 183-188. doi: 10.1111/j.1600-0447.1977.tb03561.x
119. Wang, J. F., Azzam, J. E., and Young, L. T. (2003). Valproate inhibits oxidative damage to lipid and protein in primary cultured rat cerebrocortical cells. Neuroscience 116, 485-489. doi: 10.1016/S0306-4522(02)00655-3
120. Wei, H., Qin, Z. H., Senatorov, V. V., Wei, W., Wang, Y., Qian, Y., et al. (2001). Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience 106, 603-612. doi: 10.1016/S0306-4522(01)00311-6
121. Wood, N. I., and Morton, A. J. (2003). Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the huntington's disease mutation. Brain Res. Bull. 61, 375-383. doi: 10.1016/S0361-9230(03)00141-2
122. Yoshii, A., and Constantine-Paton, M. (2010). Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Dev. Neurobiol. 70, 304-322. doi: 10.1002/dneu.20765
123. Youdim, M. B., and Arraf, Z. (2004). Prevention of MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. Neuropharmacology 46, 1130-1140. doi: 10.1016/j.neuropharm.2004.02.005
124. Young, A. H., and Hammond, J. M. (2007). Lithium in mood disorders: increasing evidence base, declining use? Br. J. Psychiatry 191, 474-476. doi: 10.1192/bjp.bp.107.043133
125. Zeevalk, G. D., Razmpour, R., and Bernard, L. P. (2008). Glutathione and Parkinson's disease: is this the elephant in the room? Biomed. Pharmacother. 62, 236-249. doi: 10.1016/j.biopha.2008.01.017
126. Zhang, X., Heng, X., Li, T., Li, L., Yang, D., Du, Y., et al. (2010). Long-term treatment with lithium alleviates memory deficits and reduces amyloid-ß production in an aged Alzheimer's disease transgenic mouse model. J. Alzheimers Dis. 24, 739-749. doi: 10.3233/JAD-2011-101875
127. Zhu, Z. F., Wang, Q. G., Han, B. J., and William, C. P. (2010). Neuroprotective effect and cognitive outcome of chronic lithium on traumatic brain injury in mice. Brain Res. Bull. 83, 272-277. doi: 10.1016/j.brainresbull.2010.07.008